Rexulti, Rxulti(brexpiprazole)
Rexulti, Rxulti (brexpiprazole) is a small molecule pharmaceutical. Brexpiprazole was first approved as Rexulti on 2015-07-10. It is used to treat major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Trade Name
FDA
EMA
Rexulti (generic drugs available since 2022-08-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brexpiprazole
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
REXULTI | Otsuka | N-205422 RX | 2015-07-10 | 6 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
rexulti | New Drug Application | 2022-11-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
major depressive disorder | EFO_0003761 | D003865 | F22 |
schizophrenia | EFO_0000692 | D012559 | F20 |
schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
BREXPIPRAZOLE, REXULTI, OTSUKA | |||
2024-12-27 | NPP |
HCPCS
No data
Clinical
Clinical Trials
86 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 4 | 18 | 3 | 1 | 26 |
Schizophrenia | D012559 | EFO_0000692 | F20 | 8 | 4 | 12 | 1 | 1 | 25 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | — | 4 | 1 | — | 6 |
Depression | D003863 | F33.9 | — | — | 5 | 1 | — | 6 | |
Psychotic disorders | D011618 | F20.81 | 1 | — | — | 1 | — | 2 | |
Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | 7 | — | — | 8 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | 3 | — | — | 5 |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | 5 | — | — | 5 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | 5 | — | — | 5 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 4 | — | — | 4 |
Borderline personality disorder | D001883 | HP_0012076 | F60.3 | — | 3 | 1 | — | — | 3 |
Dementia | D003704 | F03 | — | 1 | 2 | — | — | 2 | |
Mania | D000087122 | F30 | — | — | 2 | — | — | 2 | |
Nervous system diseases | D009422 | G00-G99 | — | — | 2 | — | — | 2 | |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | — | — | — | 1 |
Conduct disorder | D019955 | EFO_0004216 | F91 | 1 | — | — | — | — | 1 |
Attention deficit and disruptive behavior disorders | D019958 | HP_0010865 | F91.3 | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | BREXPIPRAZOLE |
INN | brexpiprazole |
Description | Brexpiprazole is a N-arylpiperazine. |
Classification | Small molecule |
Drug class | antiulcer agents (benzimidazole derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1 |
Identifiers
PDB | — |
CAS-ID | 913611-97-9 |
RxCUI | 1658314 |
ChEMBL ID | CHEMBL2105760 |
ChEBI ID | — |
PubChem CID | 11978813 |
DrugBank | DB09128 |
UNII ID | 2J3YBM1K8C (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 895 documents
View more details
Safety
Black-box Warning
Black-box warning for: Rexulti
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,355 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more